General pharmacology of DW-286a, a new fluoronaphthyridone antibiotic: Effects on central nervous, cardiovascular, and respiratory systems

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 5, 2004, Pages 641-646

  Kim, Eun Joo ^a   Shin, Won Ho ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

DW 286a; Fluoroquinolone; General pharmacology

Indexed keywords

7 [3 (AMINOMETHYL) 4 (METHOXYIMINO) 3 METHYLTETRAHYDRO 1 PYRROLYL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO[1,8]NAPHTHYRIDINE 3 CARBOXYLIC ACID HYDROCHLORIC ACID SALT; ANTIBIOTIC AGENT; DW 286 A; HEXOBARBITAL; UNCLASSIFIED DRUG; 7 (3 (AMINOMETHYL) 4 (METHOXYIMINO) 3 METHYLTETRAHYDRO 1H 1 PYRROLYL) 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO(1,8)NAPHTHYRIDINE 3 CARBOXYLIC ACID; 7-(3-(AMINOMETHYL)-4-(METHOXYIMINO)-3-METHYLTETRAHYDRO-1H-1-PYRROLYL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDRO(1,8)NAPHTHYRIDINE-3-CARBOXYLIC ACID; ANTIINFECTIVE AGENT; FLUORINE; NAPHTHYRIDINE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; GASTROINTESTINAL TRACT; GUINEA PIG; HEART CONTRACTION; HEART RATE; ILEUM; KIDNEY FUNCTION; LOCOMOTION; MALE; MORTALITY; MOTOR COORDINATION; MOUSE; NONHUMAN; RESPIRATORY SYSTEM; SEIZURE; SLEEP; STOMACH ACID SECRETION; STOMACH JUICE; STOMACH PH; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORINE; GUINEA PIGS; MICE; MICE, INBRED ICR; NAPHTHYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY SYSTEM;

EID: 16644377966     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.641     Document Type: Article

References (19)

1. Appelbaum P. C., Hunter P. A., Int. J. Antimicrob. Agents, 16, 5-15 (2000).
2. Bertino J., Jr., Fish D., Clin. Ther., 22, 798-817 (2000).
3. Blondeau J. M., Clin. Ther., 21, 3-40 (1999).
4. Lipsky B. A., Baker C. A., Clin. Infect. Dis., 28, 352-364 (1999).
5. Stahlmann R., Lode L., Drugs, 58 (Suppl. 2), 37-42 (1999).
6. Takayama S., Hirohashi M., Kato M., Shimada H., J. Toxicol. Environ. Health, 45, 1-45 (1995).
7. Oliphant C. M., Green G. M., Am. Fam. Physician, 65, 455-464 (2002).
8. Yun H. J., Min Y. H., Lim J. A., Kang J. W., Kim S. Y., Kim M. J., Jeong J. H., Choi Y. J., Kwon H. J., Jung Y. H., Shim M. J., Choi E. C., Antimicrob. Agents Chemother., 46, 3071-3074 (2002).
9. Garcia-Garrote F., Cercenado E., Marti-Pedroviejo J., Cuevas O., Bouza E., J. Antimicrob. Chemother., 47, 681-684 (2001).
10. Fung-Tomc J., Minassian B., Kolek B., Washo T., Huczko E., Bonner D., J. Antimicrob. Chemother., 45, 437-446 (2000).
11. Irwin S., Psychopharmacologia, 13, 222-257 (1968).
12. Svensson T. H., Thieme G., Psychopharmacologia, 14, 157-163 (1969).
13. Dunham W. W., Miya T. S., J. Am. Pharm. Assoc., 10, 208-209 (1957).
14. Koster R., Anderson M., De Beer E. J., Fed. Proc., 18, 412-418 (1959).
15. Swinyard E. A., Brow W. C., Goodman L. S., J. Pharmacol. Exp. Ther., 106, 319-330 (1952).
16. Woodbury L. A., Davenport V. D., Arch. Int. Pharmacodyn., 92, 97-107 (1952).
17. Shay H., Komarov S. A., Fels S. S., Meranze D., Gruenstein M., Siplet H., Gastroenterology, 5, 43-61 (1945).
18. Watts J., Maiorano L., Eur. J. Pharmacol., 138, 335-342 (1987).
19. Bolli R., Cardiovasc. Drugs Ther., 5, 249-268 (1991).